year left
short interest float
clinic stage biopharmaceut compani primarili focus
develop next gener chemotherapeut agent improv efficaci
toler profil novel therapi treatment cancer compani late-
stage develop pipelin base two individu platforms- orascoveri kinas
inhibit lead candid oraxol oral formul paclitaxel combin
compani proprietari p-glycoprotein p-gp pump inhibitor develop
treat metastat breast cancer advanc gastric cancer lead candid
kinas inhibit platform topic treatment actin keratosi
compani also recent ad two platform technolog includ t-cell receptor-
engin t-cell tcr-t arginin depriv therapi
point discuss
orascoveri platform design enabl oral deliveri chemotherapi
pump inhibitor oral formul fda approv iv cancer
drug lead candid oraxol combin oral paclitaxel
develop metastat breast cancer advanc gastric cancer p-gp pump
inhibitor design increas oral bioavail paclitaxel normal
limit p-gp pump activ gi tract prevent suffici absorpt
drug patient circul conduct sever phase studi evalu
bioavail pharmacokinet oraxol compar iv paclitaxel
demonstr compani propos oraxol dose regimen result
drug exposur time convent use dose regimen iv paclitaxel
current oraxol assess phase studi metastat breast cancer patient
result posit intend file nda drug indic
oraxol could econom benefit iv paclitaxel formul paclitaxel
current market iv kolliphor el-bas taxol albumin-bound-abraxan
kolliphor el-bas formul associ hypersensit solvent
neuropathi non-linear pharmacokinet dose limit abraxan avoid mani
setback consider expens still requir iv administr
abil dose paclitaxel oral creat potenti use frequent lower dose
treatment regimen may improv drug efficaci toler oral deliveri
elimin need long infus placement iv access devic
creat potenti infect particularli immunocompromis cancer patient
overal key benefit may set oraxol apart avail iv paclitaxel formul
result second cohort phase studi oraxol gastric cancer
initi phase studi eribulin
full data phase studi oraxol metastat breast cancer
pk data phase studi oradoxel oratecan
analyst certif disclosur pleas see page
orascoveri product current assess phase studi addit oraxol
develop sever oral chemotherapi drug employ p-gp pump inhibitor increas drug
bioavail product includ oratecan oradoxel oratopo oral eribulin combin
irinotecan docetaxel topotecan eribulin respect agent except oral eribulin current
assess phase studi pose oral administr drug result similar level drug
exposur time seen iv administr fewer advers effect abl demonstr
compar bioavail similar plasma drug exposur seen iv administr respect
chemotherapeut agent product may potenti replac current use iv formul mani
patient use treat patient toler iv administr use dose-dens therapi believ
approv oraxol could facilit develop product within orascoveri platform
kinas platform target hyperprolif skin disord cancer also develop
small molecul act interf microtubul activ requir proper cell divis inhibit
kinas protein often overexpress multipl cancer type hyperprolif skin disord actin
keratosi ak psoriasi topic formul current assess two pivot phase studi
ak posit result interim analys report juli indic studi achiev primari endpoint
clearanc ak skin lesion day addit year follow data expect present year
sign partnership deal almiral bme alm well-posit dermatology-focus pharmaceut
compani give exclus right commerci us europ retain ownership right
rest world includ australia repres key market ak patient topic
also develop treatment psoriasi taiwan addit platform product includ oral
develop treatment variou solid tumor analog oral abil
permeat blood-brain-barri develop treatment glioblastoma multiform brain
improv conveni side effect profil could market driver lesion-target destruct
therapi particularli cryosurgeri domin ak treatment market topic therapi significantli less popular
requir longer durat treatment typic week associ unpleas side effect
skin irrit inflamm eros ulcer result non-compli phase ii phase trial
demonstr efficaci day consecut treatment highlight drug favor side
effect profil local skin reaction report studi mild transient data studi
expect later year overal topic treatment market ak larg under-penetrated patient
opt lesion target destruct therapi due conveni superior side effect profil howev treatment
shown avoid pitfal current avail topic treatmentsprolong applic period
burdensom side effectsphysician patient may view favor option
recent made addit pipelin juli announc expans pipelin
establish joint ventur xiangxu life scienc xlifesc known research
develop commerci t-cell receptor-engin cell tcr-t use xiangxu tcr immunotherapi
technolog known hatac technolog consist solubl high bind affin cell receptor express
engin t-cell abil target hla-antigen peptid complex cancer cell also
announc in-licens world-wide right singl isom pegyl genetically-modifi human arginas
pegtomarginas avalon polytom hk ltd subsidiari avalon biomed manag updat
program expect futur
juli close privat place debt equiti financ deal percept advisor llc
gener gross proce million net aggreg proce total million deal includ
year secur loan million issuanc million worth common share
purchas price per share addit compani enter joint ventur xiangxu life
scienc xlifesc establish oper manag limit liabil compani axi therapeut limit
xlifesc axi therapeut respect per term agreement
requir make million capit contribut ventur follow establish
axi enter licens agreement xlifesc licens tcr-t immunotherapi technolog
develop commerci oncolog product make million up-front payment
form common stock licens
first half result august report financi result first half year
end june revenu six month total million compar million
increas larg due million up-front licens fee relat partnership deal almiral
million increas sale specialti product within athenex commerci platform cost sale
first half year million compar million period increas
attribut million million increas cost sale recent launch specialti product
sale api product respect expens amount million compar
million sg expens total million million compani
report net loss million per share first half compar net loss
million per share correspond period compani cash posit june
million compar cash posit million decemb
tabl content
clinic develop oraxol
clinic develop breast cancer
clinic develop gastric cancer
oral taxan product develop
competit landscap oraxol
orascoveri pipelin product develop
treatment actin keratosi
clinic develop actin keratosi
competit landscap actin keratosi
psoriasi
glioblastoma multiform
risk invest
clinic stage biopharmaceut compani focus develop next
gener chemotherapeut agent intend improv efficaci toler profil
novel therapi treatment cancer compani late-stag develop pipelin base two individu
platforms- orascoveri kinas inhibitionboth appli well understood scientif concept
discoveri novel treatment compani also recent ad two platform technolog includ t-
cell receptor-engin t-cell tcr-t arginin depriv therapi orascoveri platform
origin discov krx licens compris product
combin proprietari p-glycoprotein p-gp pump inhibitor oral version alreadi approv
intraven chemotherapeut agent pursu approv lead candid oraxol
oral paclitaxel metastat breast cancer via pathway advanc gastric cancer result
phase studi demonstr compar oral bioavail oraxol convent use dose iv taxol
paclitaxel known anti-tumor activ current oraxol assess phase studi
metastat breast cancer patient full data anticip middl per discuss fda
posit data phase studi could suffici nda file oraxol indic
secondari indic result on-going phase studi oraxol combin nyse
cyramza ramucirumab advanc gastric cancer patient expect fourth quarter remain
product within platform includ oratecan oradoxel oratopo eribulin combin
irinotecan docetaxel topotecan eribulin respect product except oral eribulin preclin
current assess phase studi
kinas inhibit platform product includ two molecul inhibit tubulin polymer famili
tyrosin kinas sfk implic number prolif skin disord cancer lead
candid topic treatment actin keratosi ak psoriasi secondari indic
posit interim data two on-going pivot studi ak patient shown success treat skin
lesion fewer advers effect current market topic agent oral formul
develop treat solid liquid tumor analog demonstr abil
penetr blood brain barrier current develop glioblastoma multiform gbm notabl
enter sever partnership facilit clinic develop commerci market
product across multipl global territori figur show clinic pipelin phase develop
product orascoveri kinas platform note compani tcr-t immunotherapi
modifi human arginas preclin candid shown pipelin schemat
addit global suppli chain platform manufactur activ pharmaceut ingredi api
use compani research develop clinic studi well sold global pharmaceut
custom platform includ polym therapeut inc chongq taihao pharmaceut co ltd
collect known polym athenex pharma solut ap facil
commerci platform compris athenex pharmaceut divis end
ap activ commerci product product us respect
current one activ pharmaceut ingredi api manufactur facil locat china
acquir second china-bas api facil construct second plant expect use
product enter commerci stage compani also oncolog drug pilot plant
acquir locat new york state facil provid current good manufactur practic
cgmp manufactur packag laboratori servic support compani clinic develop
receiv million ny state govern develop second larg scale high-pot oncolog gmp
manufactur facil also expect use commerci stage construct facil
underway expect complet relianc manufactur limit
potenti disrupt paclitaxel avail furthermor global shortag paclitaxel may
abl control meaning portion market paclitaxel api manufactur
develop sever product within orascoveri platform leverag compani proprietari
p-glycoprotein p-gp pump inhibitor technolog enabl oral deliveri chemotherapeut agent
typic administ intraven lead orascoveri product candid oraxol combin p-gp pump
inhibitor oral version paclitaxel result phase bioavail studi demonstr
compar bioavail oraxol convent use dose iv taxol paclitaxel base measur
total area curv metric total drug exposur studi highlight potenti efficaci oraxol
patient treat drug level overal system paclitaxel exposur well known
anti-tumor activ orascoveri platform product includ oratecan oradoxel oratopo eribulin
combin irinotecan docetaxel topotecan eribulin respect compani
pursu approv oral treatment indic iv formul respect
chemotherapeut agent alreadi approv
partnership enter sever key partnership clinic develop commerci
orascoveri platform product variou minor territori orascoveri technolog origin develop
korean base compani krx grant exclus right
develop commerci product deriv orascoveri program indic throughout
world hanmi still maintain right orascoveri product korea hanmi conduct earli
phase trial differ orascoveri platform product zenith technolog corpor privat
affili zenrx enter collabor licens agreement grant zentech commerci
right oraxol oratecan new zealand australia zentech new zealand-bas independ contract
research organ base term agreement first clinic studi oraxol complet new
zealand also enter collabor suppli agreement eli lilli nyse
develop oraxol two compani current conduct phase ib studi evalu oraxol
combin eli lilli cyramza ramucirumab vascular endotheli growth factor vegf receptor inhibitor
patient advanc gastric esophag cancer addit execut target licens agreement
taiwan-bas compani pharmaessentia tpex grant latter compani right develop
market oraxol oratecan taiwan singapor vietnam believ strateg partner allow
focu develop commerci product unit state key
market yet also posit potenti financi benefit drug approv market territori
across world
develop oraxol oral paclitaxel treatment metastat breast cancer
advanc gastric stomach cancer pursu fda approv former indic via pathway
oraxol combin p-gp pump inhibitor oral version anti-canc drug paclitaxel receiv fda
approv p-gp pump inhibitor shown significantli increas
bioavail oral administ paclitaxel pharmacodynam drug compar
observ iv paclitaxel phase studi demonstr dose oraxol result
similar total area curv auc total drug exposur time convent iv
taxol dose known anti-tumor activ point potenti oraxol serv treatment
solid malign histor treat iv paclitaxel oral deliveri paclitaxel offer
practic advantag easier administ intraven paclitaxel well clinic advantag once-
weekli dose rather convent dose-dens once-everi three week schedul use once-weekli dose
schedul shown increas total drug exposur time decreas cmax relat advers effect creat
potenti greater efficaci toler current assess oraxol phase bioequival
studi phase studi evalu efficaci oraxol metastat breast cancer patient phase ib studi
gastric cancer patient final result breast cancer studi expect middl result
second cohort studi gastric cancer patient expect
mechan action
novel select p-glycoprotein p-gp pump inhibitor design permit oral
deliveri chemotherapi agent previous limit sole intraven deliveri histor oral
deliveri anti-cancer drug made difficult due poor bioavail mani chemotherapi agent
high affin p-glycoprotein multidrug transport found surfac gastrointestin tract thu
drug diffus cell line gastrointestin gi tract p-gp transport pump drug back
lumen prevent absorpt blood stream select potent inhibitor p-gp pump
design increas oral bioavail prevent transport anti-canc drug back gi lumen
shown figur increas amount drug enter circul creat potenti oral
administr becom viabl method drug deliveri local activ inhibit p-gp
exclus gastrointestin tract
figur p-gp inhibit
paclitaxel background paclitaxel approv intraven treatment ovarian gastric non-smal cell lung
cancer oraxol current develop combin oral treatment breast gastric
cancer paclitaxel antitumor drug target microtubul intracellular protein structur involv
cellular divis compris individu tubulin protein subunit bind one anoth form longer
microtubul structur cell divis known mitosi microtubul form mitot spindl facilit
align cellular chromosom along metaphas plate subsequ separ chromosom
two daughter cell order mediat process microtubul assembl disassembl
addit remov tubulin subunit paclitaxel microtubul stabil drug promot polymer
tubulin subunit stabil exist microtubul prevent disassembl subunit inhibit
progress mitosi caus cell cycl arrest ultim cell death cell-specif agent particularli
cytotox activ divid
rational oral deliveri paclitaxel paclitaxel poorli solubl water current market
intraven formul known taxol contain solvent kolliphor el castor oil
associ host treatment setback includ hypersensit solvent neuropathi dose
limit addit kolliphor el caus non-linear pharmacokinet paclitaxel propos mechan
kolliphor el form micel entrap paclitaxel limit tissu distribut elimin kolliphor
el-fre paclitaxel shown exhibit linear oral deliveri paclitaxel could allow
treatment circumv toxic pharmacokinet issu associ kolliphor el-bas paclitaxel
albumin bound paclitaxel intraven formul becam avail manufactur celgen
celg known abraxan nab-paclitaxel formul becom key altern paclitaxel
agent metastat breast cancer patient shown greater anti-tumor effect use
without need pre-med prevent hypersensit reaction howev note consider
expens gener kolliphor el-bound
current treatment regimen base classic dose-intens chemotherapi theori postul
maximum toler dose greatest anti-tumor activ howev expos patient
sever side effect alway effect kill tumor cell pharmacokinet paclitaxel
administ intraven everi three week shown figur number shown reflect
follow key point infus drug result high cmax maximum plasma concentr well
exce approxim effect exposur concentr increas toxic drug decreas drug
toler time expos treatment also sub-optimal auc proport total amount drug
absorb repres total drug exposur time case auc indic time
patient expos effect concentr drug less week due major side effect associ
paclitaxel infus hypersensit neutropenia neuropathi infus must schedul week
interv enabl reason toler
lim md phd hs et al predict efficaci oral paclitaxel formul model
pharmd comapr medic patient metastat breast cancer receiv taxan therapi
figur pharmacokinet paclitaxel deliv intraven week interv
low-dos metronom ldm chemotherapi altern convent regimen ldm chemotherapi
involv continu exposur rel low dose anti-canc drug frequent administr schedul
fewer drug-fre period unlik chemotherapi directli aim kill malign
cell ldm chemotherapi inhibit tumor angiogenesi format new vessel requir suppli blood
grow tumor vitro vivo preclin studi demonstr ldm chemotherapi paclitaxel result
anti-tumor activ via inhibit angiogenesi result also confirm human phase
ii studi employ infus low dose paclitaxel random phase clinic studi metastat
breast cancer patient demonstr frequent weekli administr paclitaxel rather typic
intraven regiment greater treatment effect howev continu drug exposur via prolong infus
weekli basi impract particularli inconveni patient current treatment regimen call
weekli paclitaxel administr howev standard therapi typic dose interv advent oral
deliveri mechan administ paclitaxel would allow weekli dose close align propos
ldm treatment regimen would result greater drug exposur potenti greater treatment efficaci
shown similar similar area curv auc iv taxol oraxol describ greater
detail clinic develop oraxol section report furthermor oral deliveri use ldm-like
treatment regimen could improv drug toler increas patient conveni complianc
pathogenesi cancer diseas caus uncontrol cell divis abnorm cell particular tissu due
lack respons normal growth control mechan case uncontrol divis lead
develop tumor may benign malign process tumor format begin tumor
initi genet alter cellular dna lead abnorm prolifer singl cell
result format popul clonal deriv tumor cell tumor progress continu surround
tumor promot agent may may carcinogen act transform cell addit
mutat occur mutat may afford one cell abil divid quickli surround tumor cell
cell divis continu cell contain mutat becom domin within tumor popul process
known clonal select clonal select continu tumor develop caus tumor divid rapidli
becom increasingli malign cancer fulli develop malign tumor abil invad
destroy underli tissu tumor produc protein stimul angiogenesi process new blood
vessel format enabl flow blood nutrient requir suppli tumor vessel
easili damag penetr allow tumor cell enter spread lymphat vessel distant organ
metastasi occur secondari tumor deriv cell primari tumor manifest distant
sever type cancer name tissu aris develop
cancer may influenc specif risk factor increas likelihood tumor-caus genet mutat
occur current pursu approv oraxol treatment metastat breast advanc
breast cancer common cancer women lead caus cancer-rel death women
world-wide estim newli diagnos case breast cancer us make
approxim new case risk factor diseas includ old age strongest risk
factor famili histori breast cancer prolong exposur estrogen chest radiat presenc prolif
breast diseas pregnanc advanc matern age obes alcohol consumpt genet risk factor includ
inherit mutat breast cancer suscept gene common sign
breast cancer breast lump mass symptom includ chang breast thicken swell
tender skin irrit nippl
screen diagnosi self-breast clinic breast exam serv primari sourc breast cancer screen
women reach exam aim identifi abnorm mass lump part normal anatomi
yearli mammographi imag becom standard care mammographi gold standard breast
imag howev mri sensit use high risk patient women whose breast
well visual mammographi ultrasound use adjunct mammographi mri high risk patient
dens breast tissu diagnosi breast cancer involv obtain complet histori physic examin
well diagnost use modal describ image-guid
stage upon diagnosi patient evalu tumor stage presenc biomark may
guid prognosi treatment estrogen progesteron receptor express serv weak prognost indic
use determin hormon therapi incorpor patient treatment regimen human
epiderm growth factor receptor known proto-oncogen presenc surfac receptor
predict factor respons certain therapi specif /neu antibodi target therapi
stage done base american joint commiss cancer ajcc guidelin includ tumor-node-
metastasi tnm classif system clinic classif system complet stage requir assess
radic et al pathogenesi neoplasia oncol suppl
develop caus cancer cell molecular approach edit
shah et al pathogenesi prevent diagnosi treatment breast cancer world clin oncol
tumor size invas local tissu skin characterist breast presenc local metastasi
region lymph node presenc metastasi distant tissu clinic classif system stage
breast cancer stage stage iv base result tnm stage
treatment diagnosi stage breast cancer treatment usual involv surgeri follow radiat
system chemotherapi hormon target biolog therapi combin treatment breast
conserv therapi bct involv surgeri remov tumor surround breast tissu wherea total
mastectomi involv remov breast tissu radiat therapi requir patient receiv breast-
conserv surgeri prevent local cancer recurr breast well patient tumor greater
cm presenc cancer lymph node
system therapi includ chemotherapi hormon therapi target biolog therapi hormon therapi
tamoxifen select estrogen modul drug aromatas inhibitor use patient estrogen-
receptor-posit er tumor roch vtx rog vx herceptin trastuzumab biolog therapi target
tumor express human epiderm growth factor receptor protein neoadjuv chemotherapi
deliv prior surgeri increas patient elig bct adjuv chemotherapi involv
administr anti-cancer agent follow surgeri radiat aim improv disease-fre surviv
overal surviv os rate associ surgeri radiat alon thought elimin residu local
distant residu microscop metastat diseas guidelin adjuv chemotherapi vari depend natur
tumor term hormon receptor posit neg express human epiderm growth
factor receptor paclitaxel use treat breast cancer dose dens
regimen standard therapi call administr paclitaxel everi week howev altern
regimen util weekli paclitaxel dose schedul standard chemotherapi agent use neoadjuv
adjuv therapi breast cancer list categori figur typic combin drug use
sever anti-canc agent well list also use salvag therapi treat advanc breast
figur agent use neoadjuv adjuv chemotherapi
treatment metastat breast cancer depend number factor includ tumor burden prior treatment
patient overal health thu treatment regimen advanc diseas vari patient patient may
shah et al pathogenesi prevent diagnosi treatment breast cancer world clin oncol
receiv combin monotherapi aforement anti-canc agent receiv paclitaxel
weekli schedul prefer though patient may receiv treatment everi week set metastat
diseas predetermin durat treatment therapi may continu diseas progress
success beyond best respons mainten therapi may also discontinu drug toxic becom
gastric cancer common malign men women repres third fifth lead caus
cancer death group respect strongest risk factor diseas chronic infect helicobact
pylori pylori bacteria commonli found stomach associ recurr stomach ulcer presenc
bacteria found approxim new stomach cancer case risk factor includ obes
smoke dietari factor stomach cancer typic develop slowli period sever year pre-cancer
chang may occur inner line stomach usual asymptomat may go unnot long
period cancer progress patient like experi non-specif symptom decreas appetit weight
loss abdomin pain/discomfort heartburn nausea earli satieti vomit blood blood
diagnosi stage gastric cancer diagnos base patient histori physic exam imag test
upper endoscopi ultrasound magnet reson imag mri positron emiss tomographi pet
invas procedur like tissu biopsi patient diagnos adenocarcinoma account
case lymphoma gastrointestin stromal tumor gist carcinoid less common type gastric
upon diagnosi patient stage use previous describ american joint commiss cancer
ajcc guidelin guidelin includ tumor-node-metastasi tnm classif system clinic
classif system stage
treatment treatment gastric cancer depend part stomach cancer origin far
cancer spread stomach wall nearbi organ potenti cur treatment
gastric cancer surgic resect part entir stomach surgeri compon treatment plan patient
cancer classifi stage surgeri alon typic suffici earli stage cancer stage
approxim patient diagnos advanc stage diseas surgeri local therapi
longer effect advanc stage patient periop chemotherapi either neoadjuv adjuv
therapi increasingli becom compon treatment regimen howev lack consensu regard
optim treatment chemotherapi may use shrink size tumor prior surgeri
target cancer spread distant organ although best chemotherapi regimen establish
uptod system treatment metastat breast cancer women chemotherapi
global cancer fact figur third edit american cancer societi
sign symptom stomach cancer american cancer societi
global cancer fact figur third edit american cancer societi
global cancer fact figur third edit american cancer societi
diagnosi stomach cancer american cancer societi
newton ad et al neoadjuv therapi gastric cancer current evid futur direct gastrointest oncol
flot docetaxel oxaliplatin leucovorin dcf docetaxel cisplatin
regimen shown surviv benefit regimen typic use first-lin treatment
radiat target antibodi therapi roch vtx rog vx herceptin trastuzumab
nyse cyramza ramucirumab target human epiderm growth factor receptor
vascular endotheli growth factor vegf receptor respect also commonli use conjunct
chemotherapy/surgeri due frequenc late-stag diagnosi patient often requir second-lin treatment
first line therapi fail weekli paclitaxel therapi long mainstay second-lin treatment regimen
advanc gastric cancer cyramza ramucirumab vascular endotheli growth factor vegf
agonist receiv fda approv use paclitaxel combin therapi gastric
adenocarcinoma advanc despit fluoropyrimidin platinum-contain chemotherapi approv base
result random control phase rainbow trial demonstr paclitaxel plu
ramucirumab significantli extend median overal surviv compar paclitaxel plu placebo combin
sinc approv combin cyramza weekli paclitaxel becom recogn new
standard second-lin treatment nation comprehens cancer network european societi medic
iv paclitaxel market taxol import agent treatment breast cancer sinc receiv fda
approv due reason toler lack cross-resist key chemotherapi agent
specif sinc sever gener taxol formul launch multipl
compani significantli reduc revenu gener sale first patent formul
gener version use solvent kolliphor el previous describ fda ema
respect approv abraxi bioscienc albumin-bound paclitaxel abraxan second line therapi metastat
breast cancer patient resist anthracyclin taxan regimen abraxi bioscienc later acquir
celgen celg sinc abraxan receiv approv first line treatment non-
small cell lung cancer metastat pancreat cancer sale drug increas million
coordin sale taxol declin significantli billion peak
approxim million declin larg attribut gener competit abraxan superior
side effect profil greater efficaci term overal respons surviv make prefer drug
taxol combin sale two paclitaxel agent exceed billion figur show sale trend
taxol abraxan sinc respect approv notabl sale figur repres use drug
earl md frcp ce et al adjuv neoadjuv treatment gastric cancer uptod
kataouni et al nab-paclitaxel second line treatment advanc gastric cancer multicent phase studi
takahari second-lin chemotherapi patient advanc gastric cancer gastric cancer
perez ea paclitaxel breast cancer oncologist
sofia et al battl nano paclitaxel advanc drug deliveri review
celgen compani earn press releas
sofia et al battl nano paclitaxel advanc drug deliveri review
across approv indic abraxan approv treat gastric cancer patient still treat
kolliphor el-bas paclitaxel anoth taxan docetaxel total averag cost one full cours cycl
taxol approxim compar total cost one full cours abraxan
figur taxol abraxan sale
breast cancer common caus cancer women make cancer diagnosi women
world-wide approxim million new case diagnos world-wide approxim
case occur us/canada europ respect diagnos incid breast cancer higher
develop countri surviv rate tend higher well approach
estim million women us breast estim new
case breast cancer diagnos us despit number treatment option patient us
expect die
breast cancer treatment regimen base larg cancer stage figur show breast cancer treatment
pattern cancer stage femal breast cancer patient account breast cancer patient
data base survey conduct american cancer societi earli state stage i/ ii patient
stage patient underw chemotherapi addit surgeri mastectomi breast conserv
surgeri stage iv metastat patient receiv chemotherapi addit surgeri receiv
radiat therapi and/or chemotherapi late stage patient chose forego treatment
number adjust stage iv patient elect receiv treatment underw
global cancer fact figur third edit american cancer societi
cancer treatment survivorship fact figur american cancer societi surveil servic
chemotherapi addit surgeri patient underw radiat therapi and/or
overal chemotherapi integr part treatment signific portion earli stage patient use
overwhelm major stage stage iv patient
american cancer societi surveil health servic research
pursu approv oraxol metastat stage iv breast cancer therefor look command
share market current occupi taxol iv paclitaxel abraxan lack epidemiolog data
metastat breast cancer mbc specif incid recurr diseas studi use well-establish
back-calcul method known moral incid approach model use forecast preval
incid mbc base mortal surviv data surveil
epidemiolog end result seer registri studi estim approxim patient would
diagnos mbc either new diagnosi diseas recurr
figur show potenti us market opportun oraxol metastat breast cancer total market
opportun shown figur base scenario analysi market penetr vari
potenti conserv estim account follow key consider iv administ abraxan
taxol well-establish system treatment stage iv patient elect forego treatment
altogeth patient may treat non-taxan anti-cancer agent also assum price oraxol
line abraxan given benefit oral formul gener taxol
cancer treatment survivorship fact figur american cancer societi surveil servic
mariotto ab et al estim number women live metastat breast cancer unit state cancer
figur potenti us market opportun oraxol metastat breast cancer
number treat
treatment
believ approv oraxol may abl command sizeabl portion market potenti greater
given benefit offer abraxan taxol includ greater efficaci potenti superior
toler easier mode administr howev even moder market penetr treatment
newli diagnos recurr metastat diseas oraxol repres sizeabl market opportun
also note scenario analysi account rest world sale could repres meaning
gastric cancer fourth common malign world approxim case
occur world-wide case occur develop countri half world total occur eastern
asia primarili china record new estim
new case us eu rate stomach cancer men nearli twice high seen
women unit state case diagnos earli due preval advanc
diseas result late-stag diagnos mortal rate gastric cancer somewhat high five-year surviv
patient diagnos earli stage diseas approxim drop less diseas diagnos
stage iib unit state surviv rate record metastat gastric cancer
fatal mean overal surviv month surviv
per studi evalu data newli diagnos gastric cancer patient im
health oncolog databas patient underw first-lin chemotherapi treat first line
global cancer fact figur third edit american cancer societi
globocan estim cancer incid mortal preval world-wide intern agenc
research cancer world organ
global cancer fact figur third edit american cancer societi
kataouni et al nab-paclitaxel second line treatment advanc gastric cancer multicent phase studi
lm et al chemotherapi treatment patter cost outcom patient gastric cancer unit state
retrospect analysi electron medic record administr claim data gastric cancer
chemotherapi went receiv second-lin treatment nyse cyramza ramucirumab
paclitaxel consid standard care second-lin treatment gastric cancer us europ
pursu approv oraxol use second-lin therapi advanc gastric cancer combin
cyramza thu compani aim product replac iv paclitaxel compon current use
combin therapi patient would treat cyramza monotherapi due inabl toler weekli
iv paclitaxel may abl toler oral paclitaxel combin cyramza thu also part
address market appli treatment pattern describ patient undergo first-lin
therapi patient receiv second-lin therapi patient becom newli diagnos
gastric cancer approxim would ultim undergo second-lin treatment iv paclitaxel
howev given improv toler profil oraxol expect higher proport patient would elect
treatment figur summar address us market patient may pursu second-lin treatment
advanc gastric cancer
figur us market estim oraxol advanc gastric cancer
newli diagnos
line treat
oraxol price similarli abraxan base previous describ benefit efficaci potenti
toler mode administr total market opportun oraxol indic us
million annual overal market penetr may influenc follow factor combin
cyramza paclitaxel becom first choic second line therapi among treat oncologist patient must
optim cyramza paclitaxel therapi may elig combin
previous treat paclitaxel agent could increas resist second-lin therapi patient may
toler paclitaxel therefor may receiv cyramza monotherapi patient may treat altern
non-taxan base regimen approv believ oraxol could command signific share market
second-lin therapi combin cyramza
note us repres small portion global market gastric cancer less newli
diagnos case occur us market opportun china significantli larger account nearli
annual case world-wide base epidemiolog data approxim case new case
gastric cancer occur china patient diagnos advanc diseas patient receiv
helwick et al ramucirumab paclitaxel improv overal surviv first progress metastat gastric cancer
post-op adjuv assum patient receiv first line chemotherapi
undergo second-lin treatment similar trend unit state approxim may treat
oraxol base market size china could repres key market gastric cancer indic
clinic develop oraxol
conduct sever clinic studi assess safeti efficaci pharmacokinet oraxol patient
solid tumor compani complet two phase studi determin maximum toler dose oraxol
well recommend phase ii dose base result studi phase bioavail studi
compani decid move forward dose regimen oraxol consecut day per week
futur clinic studi result bioavail studi demonstr compar bioavail
oraxol convent use dose iv taxol paclitaxel base measur total area curv
metric total drug exposur highlight potenti efficaci oraxol patient treat drug
level paclitaxel exposur well known anti-tumor activ
term on-going studi current conduct phase bioequival studi evalu
pharmacokinet chosen oraxol dose phase studi evalu efficaci oraxol
metastat phase breast cancer patient phase ib studi gastric cancer patient januari
receiv posit feedback fda design on-going phase trial breast cancer patient
agenc intim success achiev primari endpoint along accept benefit risk
profil could adequ singl compar trial support registr oraxol metastat breast
full result expect report middl compani also conduct phase ib trial
collabor nyse evalu oraxol cyramza ramucirumab combin therapi gastric
cancer patient result first cohort encourag patient show partial respons
patient show stabl diseas patient show diseas progress compani proceed
second cohort studi result expect
phase studi open label phase dose escal studi evalu safeti efficaci
oraxol patient advanc solid cancer patient dose tablet oral formul
paclitaxel given day cycl cycl evalu dose paclitaxel rang
dose half paclitaxel dose rang
primari endpoint determin maximum toler dose base dose limit
toxic evalu day cycl reach dose escal stop
plateau observ plasma drug level dose
yang et al gastric cancer treatment similar differ china korea transl gastroenterol hepatol
us phase studi open label phase ib dose escal studi assess pharmacokinet
safeti oraxol patient advanc stage malign first cohort patient receiv mg dose
oraxol day per week week cycl patient subsequ cohort receiv
day per week week cycl oraxol administ two tabletsa mg capsul
paclitaxel tablet total patient enrol subject
expans cohort highest test weekli dose day per week primari endpoint studi
determin maximum toler dose oraxol secondari endpoint determin
recommend phase ii dose reach studi indic oraxol dose
mg per day day per week well
phase bioavail studi open-label phase studi assess bioavail oraxol
compar absorpt iv paclitaxel total subject enrol dose follow mg
oraxol mg oraxol mg oraxol mg
investig compar pharmacokinet pk valu patient receiv oraxol
twice weekli patient receiv taxol dose weekli
figur show blood paclitaxel concentr patient receiv oraxol paclitaxel mg
twice weekli receiv taxol weekli total area curv auc
oraxol group ng hr/ml compar ng hr/ml iv taxol group auc
proport total amount drug absorb repres total drug exposur time thu result
studi indic treatment oraxol achiev blood paclitaxel concentr time
compar plasma concentr achiev iv paclitaxel oral paclitaxel administr result
similar level total drug exposur iv paclitaxel administr
figur mean plasma concentr follow oral vs iv administr paclitaxel
point potenti efficaci oraxol patient treat drug level paclitaxel
exposur well known anti-tumor activ base pharmacokinet observ
group investig select dose regimen mg oraxol daili consecut day
per week futur studi expect regimen produc even similar exposur
paclitaxel weekli iv taxol regimen investig believ dose regimen result
longer time target plasma concentr creat potenti greater anti-canc
bioavail extens studi conduct open-label random phase cross-ov studi
compar pharmacokinet oraxol iv paclitaxel patient random one two treatment
arm oraxol consecut day per week week follow iv paclitaxel
iv paclitaxel follow oraxol dose week washout period treatment
pharmacokinet measur taken day oraxol treatment period day
paclitaxel treatment period upon complet studi patient automat enrol
extens studi continu receiv oraxol indefinit pharmacokinet data
collect end week
interim analysi conduct first patient cross-ov studi serv provid baselin
pk data oraxol paclitaxel mean auc measur hr ng/ml
hr ng/ml paclitaxel oraxol group respect cmax measur ng/ml paclitaxel
group compar ng/ml oraxol group
extens studi serv provid pk data oraxol week treatment first patient
evalu interim analysi auc first hour treatment measur patient
alreadi receiv oraxol week compar data cross-ov studi patient
baselin measur baselin group respect pk
curv patient cross-ov extens studi shown figur overal result studi
demonstr oraxol achiev compar drug exposur convent dose paclitaxel
pharmacokinet profil oraxol alter week treatment
figur pharmacokinet result cross-ov extens studi
jackson et al open label random cross-ov bioavail extens studi oral paclitaxel
oraxol compar weekli iv paclitaxel advanc solid tumor univers otago dunedin new zealand
pharmacokinet simul complet simul pharmacokinet comparison label iv taxol
administ oraxol administ daili consecut day per week
period result simul chart figur
figur pharmacokinet data iv oral paclitaxel dose regimen
aggreg oraxol auc three week measur ng/ml similar aggreg iv taxol
measur ng/ml plasma drug level ng/ml greater consid therapeut base
result simul real clinic set expect time exposur oraxol patient blood
greater ng/ml project longer iv taxol simul indic oraxol level
exceed target plasma concentr hour per cycl compar hour iv taxol
compani believ increas exposur therapeut level paclitaxel may increas efficaci drug
furthermor simul indic per week oral paclitaxel regimen associ lower cmax
maximum plasma concentr oraxol cmax reach one dose iv taxol lower cmax point
potenti decreas toxic suggest oral dose regimen could better toler among
patient compani design phase studi assess oraxol metastat breast cancer patient base
result simul comparison choos dose regimen oraxol day per week week
clinic develop breast cancer
trial design on-going open-label random phase studi evalu safeti toler tumor
respons oraxol use treat patient metastat breast cancer iv paclitaxel monotherapi
recommend oncologist approxim femal patient random receiv oraxol iv
paclitaxel ratio patient treat week treatment extens period
total week oraxol dose regimen consist mg tablet one hour dose
oral formul paclitaxel consecut day week patient compar iv paclitaxel
arm receiv label dose iv paclitaxel everi three week primari endpoint tumor
respons tumor assess use radiolog scan read blind central radiologist group use recist
guidelin scan take place week addit primari endpoint includ safeti
toler measur determin laboratori paramet advers event seriou advers event
secondari endpoint includ progression-fre surviv overal surviv interim analys
perform first occur patient complet treatment second follow treatment
total patient first analysi complet octob second complet septemb
final data expect becom avail enrol patient middl note
studi power potenti show superior versu iv paclitaxel
interim trial result independ drug safeti monitor board dsmb conduct first interim
analysi octob unanim recommend continu studi key find first
interim analysi infrequ oraxol-tr patient experienc neuropathi common symptom
treatment iv paclitaxel
octob present result studi patient metastat breast cancer mbc
european societi medic oncolog esmo patient site metastasi includ bone liver lymph
node patient site metastasi follow treatment patient achiev
partial remiss pr patient stabl diseas sd patient progress diseas
pd note patient report stabl diseas final imag studi complet
earli novemb respons rate could improv time imag figur show
chang tumor size patient evalu
figur chang tumor size follow treatment oraxol
term safeti patient experienc drug-rel advers event includ grade neutropenia
recov dose limit neuropathi report pharmacokinet profil observ week
reproduc week measur plasma auc found similar auc observ histor
standard dose intraven paclitaxel mg/kg weekli overal result highlight safeti oraxol
abil decreas tumor size slow diseas progress patient mbc also suggest total drug
exposur similar shown effect mbc
dsmb complet second interim analysi first patient septemb plan
submit unblind data regulatori author near term facilit discuss market
submiss pathway compani intend discuss serv pre-nda meet
respect final data analysi enrol target patient septemb
expect report result entir studi popul middl term regulatori path forward
januari receiv posit feedback design studi fda intim
success achiev primari endpoint along accept benefit risk profil could provid adequ
compar data support registr oraxol metastat breast cancer
clinic develop gastric cancer
singl arm open-label phase i/ii studi evalu efficaci oraxol second line treatment
advanc gastric cancer subject enrol dose oraxol consecut day per week
week term safeti oraxol found overal safe toler result phase ii
portion studi show overal median surviv month although caution compar data across
clinic studi surviv result noteworthi view context surviv data eli lilli
nyse phase studi evalu now-fda-approv cyramza ramucirumab phase
studi median surviv month month patient treat cyramza monotherapi placebo
respect second phase studi investig report median surviv month
month patient receiv cyramza iv paclitaxel combin iv paclitaxel monotherapi
analysi pharmacokinet data indic total drug exposur time measur auc
dose oraxol approxim standard iv paclitaxel dose base result phase ii studi
enter collabor agreement eli lilli evalu potenti oraxol cyramza
phase ib studi oraxol ramucirumab
on-going phase ib studi conduct collabor evalu oraxol cyramza
ramucirumab combin therapi gastric cancer patient primari object determin maximum
toler dose daili oraxol start day per week week cycl oraxol
dose combin cyramza januari report posit data first cohort
patient patient experienc partial respons tumor shrink size
patient show stabl diseas patient show diseas progress compani proceed
second cohort studi result expect
oral taxan product develop
odon promis pharmaceut compani develop tesetaxel oral taxan agent
current phase develop neg hormon receptor posit local advanc metastat
breast cancer patient previous treat taxan neoadjuv adjuv set tesetaxel
molecular structur prevent drug act upon p-gp pump provid tesetaxel
greater oral bioavail taxan drug tesetaxel also high solubl long termin half-lif
compar convent iv paclitaxel docetaxel formul featur allow oral administr
rather iv administr well favor dose regimen lastli tesetaxel formul contain
kolliphor-el solubil agent use convent iv paclitaxel decreas likelihood drug
caus hypersensit reaction odon pursu approv dose preclin studi use vitro
vivo model highlight drug potent anti-tumor activ demonstr overal less
nm vivo mous model oral tesetaxel greater growth inhibitori effect iv taxan paclitaxel
docetaxel respect inhibit rate
term clinic studi odon evalu tesetaxel clinic studi patient local
advanc la metastat breast cancer mbc well patient variou cancer type includ gastric
colorect lymphoma prostat melanoma solid tumor safeti data patient across multipl studi
shown use alon combin capecitabin tesetaxel overal safe
toler common grade higher ae treatment-rel neutropenia occur
patient receiv tesetaxel monotherapi patient receiv combin therapi febril neutropenia
experienc patient receiv monotherapi combin therapi respect efficaci data
two phase ii studi well studi design on-going phase studi outlin
phase ii studi phase ii studi evalu tesetaxel first line treatment mbc patient
neg hormon receptor hr posit neg mbc receiv oral tesetaxel first day
day treatment cycl patient escal subsequ cycl depend toler primari
endpoint object respons rate orr defin proport patient confirm complet
partial decreas sum diamet target lesion respons patient evalu respons
confirm responsebas two tumor scan least week apartwa found one patient
demonstr complet respons experienc partial respons patient exhibit stabl diseas
median month among patient month patient hr posit diseas term
safeti tesetaxel found well toler start dose escal
patient common grade higher ae neutropenia occur patient treat
start dose patient receiv escal dose hypersensit reaction
second phase ii studi patient mbc treat tesetaxel first- second- third-lin
chemotherapi patient receiv day cycl patient prior
chemotherapi receiv one prior chemotherapi regimen receiv two prior regimen
patient complet least one cycl consid evalu respons confirm orr
patient exhibit stabl diseas median time progress month studi also evalu patient
potenti taxan resist base immunohistochemistri stain p-gp pump express patient
high p-gp express exhibit complet partial respons stabl diseas show
sign diseas progress patient low p-gp express confirm respons
exhibit stabl diseas show diseas progress respect safeti tesetaxel well toler
neutropenia common grade higher ae occur patient
phase studi design current odon conduct random control phase contessa trial
evalu oral tesetaxel reduc dose capecitabin approxim neg hormon receptor
posit la/mbc patient random receiv oral tesetaxel day cycl plu
oral capecitabin day cycl approv oral dose capecitabin
per day monotherapi patient previous treat taxan neoadjuv
adjuv set primari endpoint secondari endpoint includ os orr diseas control
rate assess independ radiolog review committe given tesetaxel profil
prior data set phase trial design believ high likelihood primari endpoint
met report
korean-bas pharmaceut compani current develop lipid-bas
paclitaxel formul administ oral solut oral solut design mucoadhes
gastrointestin tract adher mucos cell stomach small intestin similar
daehwa pursu approv treatment metastat breast cancer second line
therapi advanc gastric cancer preclin studi mg/kg dose oral shown
approxim bioavail mg/kg iv taxol dose antitumor effect
agent compar iv taxol lung breast ovarian cancer model drug
approv korea base result phase studi gastric cancer patient
demonstr non-inferior compar iv paclitaxel term progress free surviv
current market brand name liporaxel term clinic develop us daehwa complet
phase phase i/ii studi patient advanc solid tumor gastric cancer plan conduct
phase ii studi breast cancer patient
phase studi patient advanc solid tumor refractori standard treatment treat singl
oral dose dose escal schedul rang one chemotherapi
cycl patient receiv iv paclitaxel subsequ chemotherapi cycl patient treat
dose level dose limit toxic observ grade advers event includ diarrhea neutropenia
fatigu grade toxic observ investig escal dose beyond
jang et al absorpt mechan oral paclitaxel formul form hydrat lipid spong phase
kang yk et al efficaci safeti find dream phase studi oral paclitaxel versu
paclitaxel patient advanc gastric cancer failur first-lin chemotherapi ann onc
pharmacokinet increas proport dose coeffici varianc
area curv rang line coeffici
record iv paclitaxel object respons observ patient show stabl diseas
overal result studi indic safe well toler patient advanc
malign dose dose use futur dose escal
phase i/iia studi phase compon studi patient cohort patient advanc
solid tumor gastric cancer treat escal dose rang
dose limit toxic includ neutropenia febril neutropenia maximum toler dose recommend
dose phase iia found twice daili day everi week phase iia
compon studi patient advanc gastric cancer fail first-lin therapi receiv
twice daili day everi week confirm partial respons observ median
progression-fre surviv patient treat maximum toler dose month common
grade advers event neutropenia leukopenia overal demonstr antitumor efficaci
deem safe well
present daehwa prepar conduct open-label phase ii studi compar iv paclitaxel
patient metastat breast cancer investig anticip enrol approxim patient primari
endpoint includ object respons rate orr expect measur everi week
month time random well diseas control rate dcr pharmacokinet paramet
auc cmax measur variou time point secondari endpoint includ overal surviv progress
free surviv qualiti life measur
overal demonstr accept pharmacokinet compar iv paclitaxel appear safe
well toler patient advanc solid tumor includ gastric cancer although result observ
earli stage trial shown activ obviou need addit efficaci data larger clinic trial
upcom phase ii studi evalu breast cancer patient may provid data creat clearer
path forward subsequ pivot studi howev phase ii trial slate begin
yet underway daehwa provid updat guidanc trial initi thu athenex oraxol
candid appear along clinic develop
competit landscap oraxol
use weekli oral paclitaxel creat potenti improv drug efficaci toler current
standard care paclitaxel chemotherapi util dose intens regimen patient receiv maximum
toler dose drug expos patient sever side effect necessit substanti break
treatment usual week enabl reason toler dose metronom ldm chemotherapi
regimen shown preclin clinic studi compar greater anti-tumor activ
regimen significantli fewer side effect particularli metastat breast cancer patient phase studi
hong ys et al phase studi mucoadhes lipid form oral paclitaxel patient advanc solid
tumor crossov comparison intraven paclitaxel investig new drug
mh et al phase i/iia studi novel oral paclitaxel formul patient advanc solid tumor
gastric cancer oncologist
demonstr frequent weekli administr paclitaxel rather typic intraven regimen
greater treatment effect term time progress overal surviv advent oral deliveri mechan
administ paclitaxel would allow weekli dose close align propos ldm treatment
regimen would result greater drug exposur potenti greater treatment efficaci furthermor
treatment lower dose decreas overal drug toxic improv toler patient complianc
potenti patient qualiti life
current market kolliphor el-bas taxol albumin bound abraxan formul
intraven deliveri one full treatment cours cycl gener taxol estim cost approxim
compar abraxan cost approxim per kolliphor el base formul
associ host treatment setback includ hypersensit solvent neuropathi non-linear
pharmacokinet dose limit treatment abraxan avoid setback
consider expens treatment gener taxol formul still requir intraven
administr abil dose paclitaxel oral creat potenti use frequent low dose treatment
regimen describ could improv overal drug efficaci toler addit oral deliveri
paclitaxel consider conveni patient would abl self-administ treatment without
need multidisciplinari team healthcar provid typic requir intraven deliveri
less cumbersom patient may reduc overal healthcar expenditur associ
complet cours chemotherapi oral deliveri also elimin need long infus placement
intraven access devic creat potenti infect particular import
immunosuppress cancer patient overal key benefitsimprov efficaci toler conveni
well decreas cost healthcar deliveri risk infectionset oraxol apart iv paclitaxel agent creat
opportun set price oraxol least par abraxan gener
million revenu
orascoveri pipelin product develop
addit oraxol develop sever oral chemotherapi drug employ p-gp
pump inhibitor increas drug bioavail product includ oratecan oradoxel oratopo eribulin
combin oral irinotecan docetaxel topotecan eribulin respect pose
oral administr drug result similar level drug exposur time seen iv
administr fewer advers effect figur list orascoveri platform product develop
abl demonstr compar bioavail similar plasma drug exposur seen iv
administr respect chemotherapeut agent product may potenti replac current
use iv formul use treat patient toler iv administr use dose-dens therapi
believ approv lead orascoveri product oraxol could facilit develop ultim
approv product within platform
sofia et al battl nano paclitaxel advanc drug deliveri review
stage
oratecan develop oratecan combin irinotecan system
chemotherapi agent approv use combin leucovorin treat metastat
carcinoma colon rectum use second line therapi metastat carcinoma colon rectum
progress despit fluorouracil therapi current sold brand name camptosar formul
intraven deliveri irinotecan member broad-spectrum anti-cancer drug class known
camptothecin specif target dna topoisomeras topo key protein involv dna replic
interact activ metabolit irinotecan topo cellular dna creat complex
ultim result lethal double-strand dna breakag cell activ also result
cell cycl arrest end phase/start phase signal indic presenc dna damag
detect s-phase checkpoint mechan improv bioavail irinotecan inhibit
activ p-gp pump thu allow irinotecan absorb circul postul oral
administr irinotecan could gener effici may improv overal efficaci
oratecan develop collabor krx previous studi
oratecan phase clinic studi patient advanc solid tumor total patient mostli gastric
colorect cancer enrol across three studi first two studi assess oratecan
monotherapi third evalu oratecan combin capecitabin oratecan
monotherapi found per cycl given daili consecut day week
mg/day week mg/day cycl term safeti investig observ dose limit
toxic event subject first studi subject second studi event includ
diarrhea neutropenia nausea vomit liver enzym elev seriou advers effect deem
possibl like definit relat oratecan includ diarrhea rash gastrointestin hemorrhag anorexia
vomit nausea enter asthenia neutropenia increas liver enzym third phase studi
evalu oratecan capecitabin combin therapi patient either stabl diseas partial
respons result treatment conduct fourth phase studi evalu maximum toler
dose bioavail oratecan administ everi week oppos once-daili dose
xu et al irinotecan mechan tumor resist novel strategi modul activ annal oncolog
regimen use previou studi key aim studi determin exposur follow oratecan
administr equival level observ follow iv irinotecan administr pk data studi
expect
oradoxel oradoxel combin oral docetaxel chemotherapi agent approv
treat breast cancer non-smal cell lung cancer prostat cancer gastric adenocarcinoma squamou cell cancer
head neck current market brand-nam taxoter docefrez formul
intraven administr docetaxel semisynthet taxan thought two-fold mechan
actionit inhibit microtubular polymer prevent progress mitosi caus cell cycl arrest
ultim cell death also attenu effect bcl-xl gene express known
regul cell previous describ design co-administ
chemotherapeut agent increas agent bioavail inhibit p-gp pump prevent absorpt
drug circul pursu approv oradoxel prostat cancer
evalu potenti oradoxel preclin studi specif efficaci p-gp
pump inhibit subsequ transport docetaxel gastrointestin cell pharmacokinet studi
rat investig observ signific increas plasma concentr docetaxel time follow oral
administr docetaxel administ human prostat cancer murin model
oradoxel shown activ oral docetaxel given oral without p-gp inhibitor similar efficaci
iv docetaxel oradoxel dose mg/kg demonstr level tumor growth inhibit
similar seen mg/kg docetaxel deliv intraven compani current conduct
us phase dose escal studi patient solid tumor start dose administ
everi week compani also conduct phase studi new zealand determin absolut
bioavail oradoxel prostat cancer patient anticip data studi becom avail
respect market opportun prostat cancer us one nine men diagnos prostat
cancer lifetim averag age year approxim new case
prostat cancer diagnos roughli new case classifi non-metastat
depend age patient aggress diseas physician may recommend activ
surveil prostatectomi radiat therapi first-lin treatment approxim patient diagnos
local prostat cancer opt activ surveil remain patient undergo
prostatectomi radiat therapi first-lin recurr rate follow latter treatment option
approxim patient repres number patient year could elig
second-lin calcul present figur addit note incid
pienta kj preclin mechan action docetaxel docetaxel combin prostat cancer semin oncol
prostat cancer increas age life expect continu increas age global popul
incid diseas like rise
figur us market opportun oradoxel local prostat cancer
prostat cancer patient us
prostatectomi
oratopo oratopo combin oral topotecan system chemotherapi agent
approv treat cervic ovarian small cell lung cancer current market brand-nam hycamtin
formul intraven administr aforement indic except small cell lung cancer
approv oral formul topotecan semisynthet deriv camptothecin act
inhibitor topoisomeras intend p-gp pump inhibitor co-administ
oral topotecan increas oral bioavail
receiv approv ind applic oratopo march initi phase clinic studi
evalu safeti efficaci drug compani seek approv oratopo use combin
therapi anti-canc agent treat variou solid tumor cancer type
eribulin pursu approv combin oral eribulin eribulin mesyl
chemotherapi agent receiv fda approv treat metastat breast cancer liposarcoma
respect market tyo trade name halaven administ
intraven eribulin analogu halichondrin microtubul depolymer agent inhibit
microtubul activ requir proper cell divis treatment agent result cell cycl arrest ultim
cell death octob announc fda accept ind applic eribulin
pursu approv eribulin combin treat multipl solid-tumor type plan
commenc clinic trial first half
hassanipour-azgomi et al incid mortal prostat cancer relationship human
platform overview current develop two kinas
inhibit platform famili tyrosin kinas sfk group non-receptor tyrosin kinas involv mani
cellular event includ mediat tumor cell prolifer surviv sfk also implic
hyperprolif skin disord malign transform keratinocyt compound also inhibit
tubulin polymer clinic valid drug mechan action current assess
potenti topic treatment actin keratosi ak psoriasi skin disord
associ hyperprolifer keratinocyt ak induc exposur uv radiat character
skin lesion potenti transform skin malign psoriasi immun mediat
genet skin disord character relaps remit inflamm skin compani report
posit interim result two pivot phase studi ak patient respect secondari indic
psoriasi current evalu partner pharmessentia phase studi also
develop oral formul observ activ agent solid liquid tumor
clinic studi compani intend complet addit studi sometim futur order select target
indic drug
develop second compound kinas platform analog
key distinguish physic properti abl cross blood-brain-barri everi oncolog
drug dual mechan action abil penetr brain tissu creat potenti treat
glioblastoma multiform gbm brain metastas receiv orphan drug design
treat glioblastoma figur list product develop kinas inhibit platform
stage develop target indic associ partnership
phase
ak- almiral us eu
malaysia
solid liquid
xiangxu pharmaceut china
mechan action develop small molecul dual-mechan action
product first mechan action involv inhibit famili tyrosin kinas sfk play role
regul multipl aspect tumor develop growth metastasi case hyperprolif skin
diseas actin keratosi ak inhibit kinas may abl prevent cellular transform
keratinocyt malign sci scc drug also act inhibit polymer tubulin
imped process cell divis lead cell death prevent excess cell prolifer interfer
tubulin polymer clinic valid method inhibit cell prolifer commonli use treatment
approach cancer
partnership decemb enter partnership almiral bme alm global
leader develop product skin-health particularli field actin keratosi per term
deal grant almiral exclus licens research develop commerci unit
state europ includ russia almiral agre pay up-front fee near-term payment
million well royalti payment start base annual net sale increment increas royalti
rate increas sale elig receiv addit mileston payment drug approv
addit indic deal afford certain co-promot right us addit right
part world includ canada central south america japan asia australia new zealand
africa view almiral import strateg partner extens expertis relat
skin-car product may abl util resourc experi optim develop
commerci almiral also recent bought dermatolog portfolio
million demonstr commit advanc drug dermatolog space also
enter partnership pharmaessentia tpex develop topic treatment
psoriasi taiwan well partnership krx oral formul
oncolog indic china partner xiangxu pharmaceut
develop oral glioblastoma multiform gbm china
treatment actin keratosi
develop topic treatment actin keratosi ak pre-malign hyperprolif
skin diseas affect approxim million american diseas character discolor scali skin
lesion result prolong exposur uv radiat potenti transform skin malign
number avail treatment option ak though patient elect receiv cryosurgeri
lesion-direct therapi despit number avail therapi ak physician often forc choos
efficaci toler patient conveni topic field direct therapi offer key clinic advantag
lesion-direct therapi abil treat subclin ak lesion go undetect exam
result across multipl clinic studi point safeti efficaci patient see complet
respons appli treatment once-daili day signific skin reaction given number
patient suffer ak us potenti malign transform essenti demand
patient ak treat could offer meaning market opportun septemb
two concurr pivot phase studi initi evalu treatment ointment
patient across two studi top-line result report juli show once-daili applic agent
consecut day result clearanc ak lesion assess day addit result
expect report time futur dermatolog confer via scientif public
pathogenesi ak result skin exposur uv radiat multipl advers effect epiderm
keratinocyt uv radiat caus mutat within keratinocyt dna oxid damag nucleic acid cell
membran lipid cell protein product reactiv oxygen speci ro ro
interrupt normal cell signal pathway caus alter prolifer case cellular destruct
absorpt uv light also increas product pro-inflammatori cytokin may caus intracellular
chang overal ak lesion form result mutagenesi inflamm oxid stress immunosuppress
impair apoptosi dysregul cell growth prolifer tissu remodel manifest red-
appear scali macul papul plaqu sun damag
ak skin lesion enter spontan remiss remain stale progress scc gene commonli affect
uv radiat includ tumor suppressor gene well ra gene c-myc proto-
activ famili tyrosin kinas sfk thought play role earli stage skin tumor
develop kinas play import biolog role keratinocyt growth differenti persist
activ sfk result cellular transform lead primari tumor develop sfk activ
shown significantli greater ak skin lesion compar seen normal skin sci scc
along spectrum cutan neoplasia classifi malign shown
exhibit even greater sfk activ seen
symptom diagnosi actin keratosi present sever clinic variant includ classic common
hypertroph atroph pigment actin cheliti classic form character red pink brown scali
rough patch skin typic less inch diamet patient tend averag lesion
commonli found head bald scalp face dorsal forearm hand area high
sun exposur lesion also commonli found lower extrem surround skin usual also show sign
solar damag ak typic diagnos clinic via skin examin although treat physician may perform
skin biopsi diagnosi uncertain differenti ak
treatment treatment ak evolv year prevent approach rather treat
lesion worsen current therapi aim erad lesion order prevent potenti
transform skin treatment larg consist either topic medic destruct therapi
surgeri cryotherapi dermabras photodynam therapi chemic peel topic medic typic
use area multipl skin lesion wherea isol skin lesion commonli treat
cryotherapi surgic procedur common approach treat ak briefli describ
cantisani et al actin keratosi pathogenesi updat new patent recent patent inflamm allergi discoveri
dodd et al actin keratosi rational manag dermatol ther heidelb
cantisani et al actin keratosi pathogenesi updat new patent recent patent inflamm allergi discoveri
ayli ee et al activ src-famili tyrosin kinas hyperprolif epiderm disord cutan pathol
padilla md et al epidemiolog natur histori diagnosi actin keratosi uptod
cohen md jl et al actin keratosi treatment compon prevent nonmelanoma skin
figur treatment option actin keratosi
 liquid nitrogen use freez lesion
destruct separ epiderm cell
 durat procedur second
 topic applic photosensit
follow exposur treatment area
light sourc caus select destruct
diclofenac retinoid
 durat treatment week
 associ advers event skin irrit
combin therapi becom increasingli use approach treat ak lesion typic involv lesion-
direct therapi conjunct field direct topic therapi enabl clearanc visibl
subclin notabl mani similar guidelin recommend treatment ak across
geographi particularli us europ australia repres key
unmet medic need sever effect treatment approach manag ak
disadvantag associ cryosurgeri wide use treatment option longer applic
period second effect treat lesion prevent diseas recurr howev freez skin
long caus pain erythema depigment hyperpigment thu physician often forc
choos efficaci toler repeat treatment often necessari recurr rate rang
within month furthermor cryosurgeri address subclin lesion use intend
treat larg surfac area skin surgic direct therapi dermabras carri risk infect
widespread scar usual use treat ak condit requir simultan treatment
padilla md et al epidemiolog natur histori diagnosi actin keratosi uptod
dodd et al actin keratosi rational manag dermatol ther heidelb
dodd et al actin keratosi rational manag dermatol ther heidelb
topic field-direct therapi gener consid less effect cryotherapi howev therapi
use long-term manag ak easili appli patient without need repeat
office-visit pain procedur sedat requir destruct lesion target treatment approach use
monotherapi topic agent shown effect treat obviou subclin ak lesion
applic topic therapi patient alreadi undergon lesion direct therapi may decreas risk
subclin lesion progress visibl lesion altern appli topic treatment prior lesion
direct therapi may highlight lesion would visibl subsequ treat
target destruct therapi use monotherapi first second-lin treatment
use combin therapi undoubtedli space topic agent treatment landscap despit
efficaci cost effect cryotherapi howev current topic agent requir sometim twice-
daili applic week also associ side effect skin inflamm irrit
ulcer may requir use corticosteroid milder formul longer period time
disadvantag may discourag patient initi choos topic treatment lesion direct therapi
may result patient non-compli given limit lesion-direct field-direct therapi
patient could certainli benefit topic therapi compromis efficaci toler conveni
preliminari result suggest topic treatment ointment result signific skin
reaction local skin reaction observ phase ii phase studi mild transient furthermor
ointment appli daili day shown effect treat lesion
limit lesion recurr treatment period consider shorter requir treatment
current avail topic agent addit result two on-going phase studi provid
safeti efficaci data expect later year posit result may point potenti kx-
satisfi need effect treatment target visibl subclin lesion conveni
applic regimen limit risk advers effect
epidemiolog risk factor ak includ sun exposur age male gender light skin pigment exposur
uv light exacerb closer proxim sun ak second common diagnosi made
dermatologist us affect approxim adult men adult women
common pre-canc us squamou cell carcinoma begin untreat ak
lesion diseas affect million american account million dermatologist
primari offic visit incid diseas appear increas world-wide due increas level
uv radiat lifestyl chang age popul notabl australia highest preval ak
world-wide estim closer popul age year older suffer
diseas higher incid relat fact ozon layer australia consider thinner
ozon cover region world
chetti et al primari review actin keratosi therapeut option global perspect dermatol ther
kirbi md ms et al variat manag actin keratosi jama dermatol
chetti et al primari review actin keratosi therapeut option global perspect dermatol ther
market estim million dermatologist primari offic visit ak annual us
treatment encourag diagnos diseas due potenti lead scc accord
nation ambulatori medic survey data approxim patient underw
procedur destroy lesion somewhat consist survey also highlight patient
and/or physician prefer lesion target
abl demonstr posit efficaci without side effect associ topic therapi
agent could captur market-shar topic agent side effect profil alreadi deter use
furthermor better toler topic physician may consid use cryosurgeri
lesion direct procedur given potenti treat subclin lesion reason could
see reason market penetr price appropri
ex-u retain right commerci key market outsid us includ canada
australia territori treatment decis typic base cost canada commonli
use treatment ak cryotherapi follow topic treatment cryosurgeri subsid
govern wherea treatment option cover patient third-parti payer patient
extend coverag increasingli opt medic treatment ingenol mebut due conveni abil
treat field ak lesion potenti treat subclin lesion
australia repres uniqu market opportun compani consid countri high preval
diseas studi conduct australia follow treatment trend ak point
grow preval diseas increas number patient receiv treatment treatment cover
univers medicar health insur scheme reimburs patient medic fee incur common
therapi use treat ak cryosurgeri although patient reimburs procedur
lesion treat studi found approxim cryosurgeri procedur
perform increas approxim procedur cost medicar system
million reimburs patient investig studi estim number cryosurgeri
procedur increas treatment cost
medicar system million patient patient current subsid newer treatment
convent daylight photodynam therapi abl obtain public privat insur
coverag drug could becom key altern treatment choic patient ex-u territori
clinic develop actin keratosi
complet sever clinic studi demonstr safeti efficaci topic
point potenti becom compon actin keratosi treatment paradigm result open-
label phase iia studi indic ointment use safe effect limit mild local
skin reaction lsr studi also highlight treatment ointment result complet
clearanc lesion locat face scalp treatment regimen septemb initi
two concurr pivot phase studi evalu treatment ointment patient across
gupta ak et al surveri offic visit actin keratosi report namc nation ambulatori
perera et al treatment actin keratosi rise australia univers melbourn
two studi top-line data report juli demonstr result similar seen phase ii studi
patient follow once-daili treatment regimen achiev complet respons day similar
observ result phase ii phase studi highlight consist term treatment efficaci
safeti profil across ak patient
trial design random double-blind vehicle-control pivot phase studi evalu
safeti efficaci treatment ak lesion face scalp patient enrol across
two studi approxim studi patient random receiv treatment topic
ointment vehicl once-daili day primari endpoint studi complet respons rate
measur day week defin patient achiev complet clearanc ak lesion
select area secondari outcom measur studi includ number sever lsr complet
respons rate measur month partial respons rate defin greater clearanc ak
lesion select treatment area proport ak lesion decreas size pharmacokinet
paramet assess patient subgroup base locat ak lesion treat face scalp
result juli report studi achiev primari endpoint
clearanc ak lesion day statist signific statist signific also achiev
face scalp subgroup report local skin reaction lsr line expect
consist observ phase ii studi studi remain on-going enrol complet
februari patient complet respons follow one year base posit result
studi intend submit pre-nda fda discuss data regulatori next-step
addit data expect present futur upcom scientif meet via scientif
trial design open-label phase iia studi assess potenti treatment ak
patient ak lesion within area face scalp receiv topic ointment
day second cohort patient enrol activ efficaci treatment group assess
patient second cohort receiv topic ointment treatment period primari endpoint
complet respons rate defin proport patient achiev clearanc
treat ak lesion face scalp day safeti pharmacokinet paramet also assess includ
number local skin reaction lsr laboratori valu number advers event month
amount level measur blood stream day
trial result februari report posit result phase ii studi patient
treatment cohort demonstr complet clearanc ak lesion day compar
treatment cohort cohort patient ak lesion locat face
ak lesion locat scalp saw clearanc day overal studi popul local skin
reaction lsr mild mostli character erythema redden flaking/sc crust
skin well swell major lsr score resolv rapidli subject report lsr
score erythema flaking/sc resolv rapidli without need medic
eros vesicles/pustul observ patient respect treatment relat
includ mild transient itch tender pain applic site treatment relat seriou
treatment discontinu term pharmacokinet level low undetect patient
competit landscap actin keratosi
improv conveni side effect profil topic therapi could market driver
lesion-target destruct therapi domin ak treatment market account annual
spend ak manag spent topic therapi common
topic therapi significantli less popular requir longer durat treatment typic week
associ host unpleas side effect skin irrit inflamm eros ulcer
result non-compli phase ii phase trial demonstr efficaci day
consecut treatment also report drug favor side effect profil local skin
reaction report phase ii phase studi mild transient data pertain side effect
profil becom avail later year via scientif public physician may also incentiv
prescrib field direct topic therapi treat multipl lesion rel low cost
furthermor topic therapi ad benefit treat subclin lesion may go unnot clinic
exam topic treatment also highlight subclin lesion subsequ target destruct therapi
overal topic treatment market ak larg under-penetrated patient opt lesion target
destruct therapi due conveni superior side effect profil treatment shown avoid
pitfal current avail topic treatmentsprolong applic period burdensom side effect
physician patient may view superior option current use topic destruct therapi
govern subsidy/pay coverag could dictat success ex-u market seek approv
us well canada europ australia plan commerci territori
partnership almiral bme alm ex-u territori particularli canada australia
treatment ak primarili cover govern provid healthcar program current australia
cryosurgeri commonli use therapi patient lesion elig procedur reimburs
newer therapi pdt elig govern subsid older topic field therapi
imiquimod cover special circumst per studi australian patient
underw cryosurgeri use topic treatment former invas procedur qualifi
govern rebat wherea latter similarli canada commonli use treatment cryosurgeri
also subsid nation pharmacar program wherea therapeut option cover
third-parti payer becom out-of-pocket patient expens ultim region patient treatment choic
base avail govern rebat strongli influenc treatment decis seem
new therapi must cover govern rebat program order see signific market
penetr abl obtain univers healthcar system coverag addit third-parti payer coverag
relev territori greater chanc patient amen use
chetti et al primari review actin keratosi global perspect dermatol ther heidelb
psoriasi
seek approv treatment psoriasi taiwan clinic develop indic
led partner pharmaessentia tpex initi phase clinic studi current
on-going psoriasi immun mediat genet skin disord character relaps remit inflamm
skin psoriasi multifactori pattern inherit sever gene increas psoriasi suscept
type psoriasi plaqu guttat invers pustular erythroderm plaqu
psoriasi account case term diseas pathogenesi psoriasi develop result complex
interact adapt innat immun system lead cytokin product t-cell
dendrit cell specif dysregul cutan cell result improp activ cytokin pathway
particularli tnf-a cytokin stimul product activ secondari inflammatori
addit immun dysfunct diseas also result alter gene express epiderm
keratinocyt caus excess cell prolifer studi shown greater activ kinas
import regul keratinocyt growth differenti over-activ lead
hyperprolifer keratinocyt contribut develop abnorm skin
psoriasi usual diagnos clinic although skin biopsi may use determin diseas subtyp treatment
psoriasi base primarili diseas sever patient treat topic formul mild
diseas treatment involv convent therapi topic glucocorticoid vitamin deriv
may use individu combin moder sever diseas convent oral therapi
system effect cyclosporin methotrex may use phototherapi photochemotherapi also
effect moder sever diseas convent therapi fail biolog consist primarili tnf-
inhibitor etanercept adilumimab infliximab use use biolog oral convent
therapi system effect alway well toler known increas risk sever infect
due immunosuppress
market inform psoriasi affect approxim world-wide popul preval higher
us canada affect roughli popul preval diseas
significantli lower taiwan affect popul estim peopl preval
diseas taiwan increas recent year may attribut chang lifestyl environment
factor increas awar psoriasi market domin primarili drug indic
moder sever diseas seen tremend growth sinc introduct biolog expect
continu grow due introduct addit system therapi increas access afford
treatment option broader accept biosimilar avail biolog given increas number
biolog merck nyse recent fda approv inhibitor illumya tildrakizumab
novarti nyse nv inhibitor cosentyx secukinumab market may becom increasingli crowd
drug intend patient moder sever diseas howev note biolog therapi
mckay leigh alter keratinocyt growth differenti psoriasi clinic dermatolog
ayli ee et al activ src-famili tyrosin kinas hyperprolif epiderm disord cutan patho
chiu hy et al psoriasi taiwan epidemiolog new treatment dermatologica sinica
expens patient and/or third-parti payer figur show biolog commonli use psoriasi
approxim annual wac usd treatment
figur commonli use biolog psoriasi
unlik biolog athenex target inflamm directli instead target overexpress
kinas cellular mitosi effort limit untoward keratinocyt prolifer thu provid may consid
use topic combin inject biolog therapi becom mainstay treatment
regimen price competit compar biolog therapi may potenti use
cheaper altern first-lin therapi physician elect begin treatment expens biolog
treatment may also serv treatment patient amen inject therapi also
potenti use combin topic agent milder diseas due uniqu mechan
action compar topic agent overal clinic trial demonstr accept safeti efficaci
could obtain meaning sale psoriasi given number patient afflict diseas willing
payer spend notabl amount money psoriasi therapi
clinic develop seek approv treatment psoriasi taiwan clinic
develop indic led partner pharmaessentia tpex initi phase
clinic studi current on-going compani provid inform regard studi design
timelin data becom avail
jesitu break cost psoriasi biolog dermatolog time
new drug approv march rtt news april http //market businessinsid com/news/stocks/new-drugs-
glioblastoma multiform
develop second compound kinas inhibit platform analog
oral drug act inhibit kinas interf tubulin polymer prevent
uncontrol mitot activ physic properti enabl permeat blood brain barrier creat
potenti use treat variou brain malign clinic develop led
partner xiangxu pharmaceut china glioblastoma multiform gbm
lead indic current assess phase clinic studi china pursu approv
use monotherapi gbm determin whether use first second
line treatment determin depend efficaci data obtain expand phase studi athenex
grant orphan drug design indic note compani own world-wide
right except china plan explor potenti brain oncolog indic
futur
preclin studi complet vivo clinic studi assess activ multipl brain
cancer cell line mice deliv oral use mous gmb tumor model gbm tumor cell
implant brain fulli immun compet mice investig compar efficaci
daili standard care chemotherapi agent temozolomid tmz base long term surviv
mice measur day result shown figur across multipl experi averag approxim
mice treat achiev long term surviv compar mice treat tmz
figur efficaci compar temozolomid mice gbm model
investig also evalu anti-tumor activ mice measur tumor size via magnet reson
imag mri base imag result appear complet erad brain tumor
visibl mri wherea placebo treat mice found larg tumor mri treatment
glioblastoma multiform gbm background glioblastoma multiform gbm common tumor
central nervou system account brain gbm case develop
primari glioblastoma normal glial cell undergo multistep process oncogenesi remain
glioma secondari neoplasm result progress lower grade brain tumor higher grade
diseas pathogenesi involv deregul checkpoint cell cycl well
activ observ gbm thought due increas activ kinas surfac
growth factor molecul activ protein class preclin studi gbm cell line
demonstr dysregul sfk signal lead aberr cellular prolifer reduc apoptosi increas
angiogenesi sfk inhibit known anti-tumor activ solid tumor compani postul
target famili kinas sfk inhibitor like could similar effect
howev note gbm particularli difficult cancer treat larg major random clinic
studi indic end fail
current standard care newli diagnos case gbm surgic resect tumor follow
radiotherapi chemotherapi commonli use chemotherapi agent oral temozolomid tmz dna
alkyl agent genentech avastin bevacizumab anti-vascular endotheli growth factor
vegf antibodi standard care second line multipl limit current use treatment
regimenssurg resect often complic tumor infiltr surround tissu radiotherapi lack
efficaci hypox brain region blood brain barrier complic deliveri anti-canc agent tumor
within gbm tumor high prolif activ regularli infiltr surround
tissu gbm remain particularli aggress cancer median surviv month
surviv rate
juli announc expans pipelin establish joint ventur xiangxu life
scienc xlifesc known axi therapeut research develop commerci t-cell
receptor-engin cell tcr-t co-own xlifesc
in-licens world-wide right intellectu properti xlifesc tcr-t immunotherapi technolog
known hatac technolog consist solubl high bind affin cell receptor express
engin t-cell abil target hla-antigen peptid complex cancer cell xlifesc wholly-
own subsidiari guangzhou xiangxu pharmaceut per term deal xlifesc
issu million worth common stock million cash xlifesc up-front payment
ahluwalia et al target glioblastoma tumor brain metastas ration preclin studi cancer lett
urbanska et al glioblastoma multiforme- overview contemp oncol pozn
ahluwalia et al target glioblastoma tumor brain metastas ration preclin studi cancer lett
urbanska et al glioblastoma multiforme- overview contemp oncol pozn
urbanska et al glioblastoma multiforme- overview contemp oncol pozn
tamimi af et al epidemiolog outcom glioblastoma glioblastoma chapter
ahluwalia et al target glioblastoma tumor brain metastas ration preclin studi cancer lett
toward joint ventur also expect pay xlifesc clinic regulatori mileston worth
million xlifesc retain right tcr-t immunotherapi technolog mainland china
also announc in-licens world-wide right singl isom pegyl genetically-modifi human
arginas pegtomarginas origin develop hong kong polytechn univers licens
avalon polytom hk ltd subsidiari avalon biomed manag molecul act anti-canc
agent deplet circul arginin ultim starv cancer cell synthes arginin
due defici ornithin transcarbamylas over-the-counter and/or arginosuccin synthetas ass two enzym
critic synthesi arginin urea cycl pegtomarginas spare normal cell synthes arginin
intracellularli shown favor pharmacokinet potenc profil preclin
decemb held patent pend patent applic
world-wide compani also in-licens patent patent applic hanmi orascoveri
platform lead compound orascoveri platform oraxol cover us china europ multipl
composit matter patent set expir octob octob exclud potenti avail
extens lead compound kinas inhibit platform also cover us china europ
composit matter patent begin expir decemb exclud potenti extens
specif own grant patent us grant patent countri
chief execut offic board chairman
johnson success pharmaceut execut extens leadership experi scientif
busi manag chairman ceo ribapharm launch second largest biotech ipo us
histori prior ribapharm serv head world-wide research develop icn
pharmaceut prior johnson serv senior director antivir therapi schering-plough johnson
contribut scientif public editorials/reviews/chapt peer review scientif journal
edit two book former manag director roth capit partner director board
chelsea therapeut chtp serv chair audit financ committe well corpor
govern committe well public privat compani current serv board porton
fine chemic list shenzhen exchang c-mer hold limit list hong kong
exchang privat compani includ avalon biomed manag limit aiviva corpor
hong kong x-tech start-up platform gener partner mentor also execut board member
chariti project vision honorari professor/adjunct professor univers hong kong hong
kong polytechn univers member advisori board school biomed scienc
chines univers hong kong johnson receiv medic degre mbb medic doctor degre md
univers hong kong also fellow royal colleg physician johnson serv
chairman board sinc incept assum role ceo mid
chief oper offic presidentathenex divis
jeffrey yordon held multipl senior manag posit pharmaceut industri last year
mr yordon founder chairman ceo market cap billion
left compani previou mr yordon american pharmaceut partner
founder compani eventu sold freseniu billion mr yordon ceo
fauld ceo founder yorpharm gensia
instrument sale compani apotex teva hospira price upward billion mr
yordon success taken four compani public compani sold signific return
sharehold mr yordon ernst young entrepreneur year induct chicago
entrepreneur fame prestigi innov award citi chicago appoint
chicago innov council appoint governor rauner illinoi sport facil author
appoint chairman board northern illinoi univers foundat
chair niu polit scienc advisori panel activ involv niu athlet program mr yordon
three children presid chicago area
rudolf success career pharmaceut industri twenti year experi global clinic
develop oper join serv dual role schering-plough sp vice presid
region head asia pacif global clinic oper vice presid global clinic develop
clinic oper posit rudolf success recruit head clinic oper china south east
asia australia taiwan south korea set infrastructur conduct global clinic trial asia pacif
schering-plough vice presid global clinic develop respons clinic
develop sp central nervou system drug global major achiev includ develop execut
bioequival registr strategi new formul temodol glioblastoma led simultan
global registr also design execut multipl global develop program earlier schering-plough
rudolf held variou clinic oper posit increas respons held similar posit chiron
corpor smith kline beecham rudolf obtain medic degre hong kong subsequ
train england member chair data monitor safeti board protocol review board
clinic trial network nation institut drug abus nation institut health usa
nih also member sever advisori panel grant review panel nih
chief busi strategi offic proprietari product
simon long career drug develop includ recent leadership role presid ceo cellectar
bioscienc presid ceo chelsea therapeut vice presid oncolog pharma busi hoffmann-
laroch life cycl leader global project leader pegasys/ifn head hepat franchis hoffmann-
laroch vice presid head drug develop shearwat corpor formerli faculti
depart pharmacolog colleg medicin univers saskatchewan obtain
phd pharmacolog long-standing career pharmaceut develop simon previous led
late stage develop commerci launch multipl proprietari pharmaceut product addit
phd pharmacolog simon obtain master scienc toxicolog concordia univers bachelor
scienc environment studi univers waterloo complet roche-sponsor
execut manag program columbia busi school
randol join ten year invest bank industri current
support compani corpor financ investor relat busi develop initi randol
previous credit suiss invest bank capit market divis hong kong advis compani
senior manag capit market merger acquisit financ transact
credit suiss randol led execut initi public offer randol graduat
chemic engin univers california berkeley oper research columbia
david bring signific scientif manageri expertis field translat pharmacolog
clinic research prior join david held leadership posit merck research laboratori
schering-plough research institut depart experiment medicin year industri
david made signific contribut success develop registr numer compound
area oncology/immuno-oncolog cardiovascular diseas hepatolog expertis cover full
spectrum therapeut modal includ small molecul liposom encapsul compound target cytotox
conjug cytokin monoclon antibodi gene therapi schering-plough kk tokyo david senior
execut clinic research streamlin research cultur within organ result numer new drug
approv japanes market
david receiv medic degre colleg medicin univers saskatchewan subsequ
train intern medicin mayo clinic rochest endocrinolog metabol univers
toronto univers california san diego david board certifi intern medicin endocrinolog
metabol fellow royal colleg physician canada
wing-kai role includ director nation center excel clinic trial research nation
univers hospit taiwan medic director roch asia/pacif capac particip
clinic develop number anti-canc drug rituxan herceptin xeloda name wing-
medic graduat univers new south wale sydney australia fellow royal australian
colleg physician also member american societi clinic oncolog wing-kai author mani
public clinic oncolog cours distinguish career wing-kai base taipei taiwan
serv presid polym therapeut sinc chairman chongq taihao
sinc special develop manufactur global sale market variou
complex activ pharmaceut ingredi api especi inject oncolog api ceo
fibrocel scienc nyse fcsc compani asia introduc first us fda approv
cell therapeut product laviv asia market respons build numer cgmp
facil china extens experi deal food drug administr china
unit state
receiv phd nanotechnolog rice univers work extens dr richard
smalley late nobel prize scholar also master degre chemic engin appli
mathemat rice univers
member leadership team teresa key contributor compani strateg initi global
expans develop overse legal matter world-wide compani lead govern relat
us oper ms bair appoint board director corpor secretari prior join
serv partner harri beach pllc nation recogn law firm success
repres advis busi client includ fortun compani complex divers matter teresa
list buffalo busi first list power women legal elit privat practic
teresa consist recogn peer journal super lawyer serv board
new york women foundat teresa receiv law degre jd univers buffalo school law
bachelor scienc busi administr bowl green state univers
risk invest
consid invest high-risk invest develop stage compani
histori take treatment market current fda approv drug portfolio
sever compani tri target indic cancer treatment pipelin especi
crowd competitor lead program yet gener pivot data limit clinic data
date furthermor earli indic efficaci necessarili translat posit late-stag result
compani may unabl obtain suffici capit fund plan develop program
regulatori risk associ develop drug may receiv fda approv
candid despit signific time financi invest regulatori approv market sell drug
guarante drug penetr market sale may meet expect investor
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
